The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Key findings from SURMOUNT-1 include a mean weight loss of 15.0% at the 5mg dose, 19.5% at the 10mg dose, and 20.9% at the 15mg dose over 72 weeks
PMID 28076635
Cartilage and Bone Research An interesting and perhaps unexpected area of published research has examined this compounds interactions with cartilage biology
reliable data could not be obtained at 5-amino-1MQ concentrations above 100 M due to inference with the NAMPT assay readout signal (Figure 4D, Table 3)
Current use is limited to research purposes under physician supervision
